Whole-body Biodistribution and Radiation Dosimetry in Monkeys and Humans of the Phosphodiesterase 4 Radioligand [(11)C](R)-rolipram: Comparison of Two-dimensional Planar, Bisected and Quadrisected Image Analyses

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2008 May 17

PMID 18482687

Citations 10

Authors

David R Sprague

Masahiro Fujita

Yong Hoon Ryu

Jeih-San Liow

Victor W Pike

Robert B Innis

Affiliations

Soon will be listed here.

Abstract

Introduction: [(11)C](R)-Rolipram is a selective radioligand for positron emission tomography (PET) imaging of phosphodiesterase 4, an enzyme that metabolizes 3',5'-cyclic adenosine monophosphate. The aim of this study was to estimate the human radiation absorbed dose of the radioligand based on its biodistribution in both monkeys and humans.

Methods: Whole-body PET images were acquired for 2 h after injecting [(11)C](R)-rolipram in eight healthy humans and three monkeys. The simple method of using a single two-dimensional (2D) planar image was compared to more time-consuming methods that used two (bisected) or four (quadrisected) tomographic images in the anteroposterior direction.

Results: Effective dose was 4.8 microGy/MBq based on 2D planar images. The effective dose was only slightly lower by 1% and 5% using the bisected and quadrisected images, respectively. Nevertheless, the two tomographic methods may have more accurately estimated the exposure of some organs (e.g., kidneys) that are asymmetrically located in the body or have radioactivity that appears to overlap on 2D planar images. Monkeys had a different biodistribution pattern compared to humans (e.g., greater urinary excretion) such that their data overestimated the effective dose in humans by 40%.

Conclusions: The effective dose of [(11)C](R)-rolipram was modest and comparable to that of other (11)C-labeled radioligands. The simple and far less time-consuming 2D planar method provided accurate and somewhat more conservative estimates of effective dose than the two tomographic methods. Although monkeys are commonly used to estimate human radiation exposures, their data gave a considerable overestimation for this radioligand.

Citing Articles

Development, Characterization, and Radiation Dosimetry Studies of F-BMS-986229, a F-Labeled PD-L1 Macrocyclic Peptide PET Tracer.

Kim J, Donnelly D, Tran T, Pena A, Shorts A, Petrone T Mol Imaging Biol. 2023; 26(2):301-309.

PMID: 38123744 PMC: 10973053. DOI: 10.1007/s11307-023-01889-4.

First-in-Human Evaluation of F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.

Wakabayashi Y, Stenkrona P, Arakawa R, Yan X, Van Buskirk M, Jenkins M J Nucl Med. 2022; 63(12):1919-1924.

PMID: 35772961 PMC: 9730922. DOI: 10.2967/jnumed.122.263838.

Impact of Region-of-Interest Delineation Methods, Reconstruction Algorithms, and Intra- and Inter-Operator Variability on Internal Dosimetry Estimates Using PET.

Lopez-Vilanova N, Pavia J, Duch M, Catafau A, Ros D, Bullich S Mol Imaging Biol. 2016; 19(2):305-314.

PMID: 27632424 DOI: 10.1007/s11307-016-1003-4.

Evaluation of the Enantiomer Specific Biokinetics and Radiation Doses of [(18)F]Fluspidine-A New Tracer in Clinical Translation for Imaging of σ₁ Receptors.

Kranz M, Sattler B, Wust N, Deuther-Conrad W, Patt M, Meyer P Molecules. 2016; 21(9).

PMID: 27598110 PMC: 6273209. DOI: 10.3390/molecules21091164.

Zanotti-Fregonara P, Innis R Eur J Nucl Med Mol Imaging. 2011; 39(3):544-7.

PMID: 22160195 PMC: 3791506. DOI: 10.1007/s00259-011-2005-8.

References

Fujita M, Zoghbi S, Crescenzo M, Hong J, Musachio J, Lu J . Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET. Neuroimage. 2005; 26(4):1201-10. DOI: 10.1016/j.neuroimage.2005.03.017. View

DSa C, Duman R . Antidepressants and neuroplasticity. Bipolar Disord. 2002; 4(3):183-94. DOI: 10.1034/j.1399-5618.2002.01203.x. View

Krause W, Kuhne G, Jakobs U, Hoyer G . Biotransformation of the antidepressant DL-rolipram. I. Isolation and identification of metabolites from rat, monkey, and human urine. Drug Metab Dispos. 1993; 21(4):682-9. View

Fleischhacker W, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C . A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 1992; 26(1-2):59-64. DOI: 10.1159/000118897. View

Mizokawa T, Kimura K, Ikoma Y, Hara K, Oshino N, Yamamoto T . The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats. Jpn J Pharmacol. 1988; 48(3):357-64. DOI: 10.1254/jjp.48.357. View

Lourenco C, Houle S, Wilson A, DaSilva J . Characterization of r-[11C]rolipram for PET imaging of phosphodieterase-4: in vivo binding, metabolism, and dosimetry studies in rats. Nucl Med Biol. 2001; 28(4):347-58. DOI: 10.1016/s0969-8051(01)00206-2. View

Brown A, Fujita M, Fujimura Y, Liow J, Stabin M, Ryu Y . Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med. 2007; 48(12):2072-9. DOI: 10.2967/jnumed.107.044842. View

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

Gunn R, Ranicar A, Yap J, Wells P, Osman S, Jones T . On-line measurement of exhaled [11C]CO2 during PET. J Nucl Med. 2000; 41(4):605-11. View

10.

Krause W, Kuhne G . Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica. 1988; 18(5):561-71. DOI: 10.3109/00498258809041693. View

11.

Lourenco C, DaSilva J, Warsh J, Wilson A, Houle S . Imaging of cAMP-specific phosphodiesterase-IV: comparison of [11C]rolipram and [11C]Ro 20-1724 in rats. Synapse. 1999; 31(1):41-50. DOI: 10.1002/(SICI)1098-2396(199901)31:1<41::AID-SYN6>3.0.CO;2-S. View

12.

Krause W, Kuhne G, Matthes H . Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica. 1989; 19(6):683-92. DOI: 10.3109/00498258909042306. View

13.

Krause W, Kuhne G . Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey. Xenobiotica. 1993; 23(11):1277-88. DOI: 10.3109/00498259309059438. View

14.

DSa C, Eisch A, Bolger G, Duman R . Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci. 2005; 22(6):1463-75. DOI: 10.1111/j.1460-9568.2005.04321.x. View

15.

DaSilva J, Lourenco C, Meyer J, Hussey D, Potter W, Houle S . Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging. 2002; 29(12):1680-3. DOI: 10.1007/s00259-002-0950-y. View

16.

Nestler E, Aghajanian G . Molecular and cellular basis of addiction. Science. 1997; 278(5335):58-63. DOI: 10.1126/science.278.5335.58. View

17.

Sprague D, Chin F, Liow J, Fujita M, Burns H, Hargreaves R . Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J Nucl Med. 2007; 48(1):100-7. PMC: 4135382. View

18.

Takahashi M, Terwilliger R, Lane C, Mezes P, Conti M, Duman R . Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci. 1999; 19(2):610-8. PMC: 6782198. View

19.

Tsukada H, Harada N, Ohba H, Nishiyama S, Kakiuchi T . Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious.... Synapse. 2001; 42(4):258-65. DOI: 10.1002/syn.10013. View

20.

Duman R, Heninger G, Nestler E . A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997; 54(7):597-606. DOI: 10.1001/archpsyc.1997.01830190015002. View